2015
DOI: 10.1186/s12885-015-1354-2
|View full text |Cite
|
Sign up to set email alerts
|

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

Abstract: BackgroundMetronomic oral vinorelbine could be a safe option for elderly patients with advanced non small cell lung cancer (NSCLC). Metronomic administration of chemotherapy leads to a cytostatic action shifting treatment target from cancer cell to tumor angiogenesis.Methods43 chemotherapy naive elderly (≥70 yrs) PS 0-2 patients with stage IIIB-IV NSCLC were prospectively recruited. Median age was 80 yrs (M/F 36/7) with predominantly squamous histology. PS distribution was 0-1(16)/2(27) with a median of 3 seri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
55
0
4

Year Published

2016
2016
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 63 publications
(62 citation statements)
references
References 19 publications
3
55
0
4
Order By: Relevance
“…Our study population included only patients with an ecog ps of 2 and multiple comorbidities; however, we found survival and efficacy rates comparable to those in the Camerini et al trials 14,21 . The lower toxicity and improved safety profile were also similar.…”
Section: Discussionsupporting
confidence: 50%
See 4 more Smart Citations
“…Our study population included only patients with an ecog ps of 2 and multiple comorbidities; however, we found survival and efficacy rates comparable to those in the Camerini et al trials 14,21 . The lower toxicity and improved safety profile were also similar.…”
Section: Discussionsupporting
confidence: 50%
“…The median pfs in the study was 5 months (range: 2-21 months), and the median os was 9 months (range: 3-29 months). In addition, the 1-and 2-year survival rates were 37.2% and 9.3% respectively 14 .…”
Section: Discussionmentioning
confidence: 96%
See 3 more Smart Citations